Single and multi‐dose pharmacology of recombinant and urinary human chorionic gonadotrophin in men
Authors' conclusion
Although hCG pharmacokinetics are not formally bioequivalent, the similar pharmacodynamic effects on serum testosterone indicate that at the doses tested both hCGs provide comparable clinical effects. The starting dose of rhCG for treating gonadotrophin-deficient men should be 62.5 µg (6 clicks) of the rhCG pen.
Study context
- Population
- Volunteers in cross-over studies and gonadotrophin-deficient men in the multi-dose study8 + 7 crossover
- Comparison
- Recombinant human choriogonadotrophin (hCG) vs urinary hCG
Methodological detailsrandomized cross-over, single-dose
- Randomized cross-over
- Single-dose
Primary result
As reported in the abstract
Serum hCG and testosterone responses after standard and high-dose injection
- Serum hCG and testosterone responses had similar timing and peak concentrations, except mildly lower early (<48 h) serum testosterone with uhCG
Further findings
Multi-dose pharmacokinetics and serum testosterone
- Both hCGs had similar pharmacokinetics; pooled half-life
- 5.8 days, p < .001
- Serum testosterone stable after injection and did not differ between hCG products
Pen use (bench testing)
- Pens used inappropriately
- 20% of pens from 4/10 individuals
Original publication
Single and multi‐dose pharmacology of recombinant and urinary human chorionic gonadotrophin in men. Clin Endocrinol (Oxf). Published 6 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →